https://www.psoriasis-news.de/neue-studien-in-deutschland/an-open-label-multi-center-protocol-for-patients-who-have-completed-a-previous-novartis-sponsored-secukinumab-study-and-are-judged-by-the-investigator-to-benefit-from-continued-secukinumab-treatment-r37/ 2026-08-07T02:00:00+02:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/optimmize-2-a-phase-3-multicenter-single-arm-open-label-extension-study-to-assess-the-safety-tolerability-and-efficacy-of-risankizumab-in-subjects-with-moderate-to-severe-plaque-psoriasis-who-have-completed-participation-in-study-m19-977-optimmize-1-r38/ 2026-08-07T02:00:00+02:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/optimmize-2-a-phase-3-multicenter-single-arm-open-label-extension-study-to-assess-the-safety-tolerability-and-efficacy-of-risankizumab-in-subjects-with-moderate-to-severe-plaque-psoriasis-who-have-completed-participation-in-study-m19-977-optimmize-1-r39/ 2026-08-07T02:00:00+02:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/effisayiltm-on-an-open-label-long-term-extension-study-to-assess-the-safety-and-efficacy-of-spesolimab-treatment-in-patients-with-generalized-pustular-psoriasis-gpp-r36/ 2026-08-05T02:00:00+02:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/effisayiltm-on-an-open-label-long-term-extension-study-to-assess-the-safety-and-efficacy-of-spesolimab-treatment-in-patients-with-generalized-pustular-psoriasis-gpp-r35/ 2026-07-29T02:00:00+02:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/a-phase-2-multicenter-randomized-double-blind-placebo-controlled-parallel-group-dose-ranging-study-of-ly4100511-dc-853-for-the-treatment-of-adult-participants-with-moderate-to-severe-plaque-psoriasis-r29/ 2026-07-25T02:00:00+02:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/a-multicenter-randomized-parallel-group-double-blind-active-controlled-study-to-evaluate-the-efficacy-and-safety-of-bimekizumab-compared-to-ustekinumab-in-children-and-adolescent-from-6-years-to-less-than-18-years-of-age-with-moderate-to-severe-plaque-pso-r30/ 2026-07-25T02:00:00+02:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/a-phase-3-multicenter-randomized-double-blind-placebo-controlled-and-deucravacitinib-active-comparator-controlled-study-to-evaluate-the-efficacy-and-safety-of-jnj-77242113-for-the-treatment-of-participants-with-moderate-to-severe-plaque-psoriasis-r32/ 2026-07-24T02:00:00+02:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/a-phase-3-multicenter-randomized-double-blind-placebo-controlled-and-deucravacitinib-active-comparator-controlled-study-to-evaluate-the-efficacy-and-safety-of-jnj-77242113-for-the-treatment-of-participants-with-moderate-to-severe-plaque-psoriasis-r34/ 2026-07-24T02:00:00+02:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/adjustable-brodalumab-dosage-regimen-compared-with-standard-brodalumab-treatment-for-52-weeks-in-subjects-with-moderate-to-severe-plaque-psoriasis-and-%E2%89%A5120-kg-body-weight-adjust-phase-4-efficacy-a-randomised-double-blind-controlled-parallel-group-multi-ce-r31/ 2026-07-23T02:00:00+02:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/effisayiltm-on-an-open-label-long-term-extension-study-to-assess-the-safety-and-efficacy-of-spesolimab-treatment-in-patients-with-generalized-pustular-psoriasis-gpp-r33/ 2026-07-21T02:00:00+02:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/a-phase-3b4-multi-center-randomized-open-label-long-term-safety-study-of-deucravacitinib-in-comparison-to-ustekinumab-in-participants-with-moderate-to-severe-plaque-psoriasis-pragmatyk-r26/ 2026-07-10T02:00:00+02:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/an-extension-study-in-patients-with-moderate-to-severe-plaque-psoriasis-to-evaluate-the-long-term-safety-efficacy-and-durability-of-response-to-esk-001-onward3-r27/ 2026-07-10T02:00:00+02:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/a-phase-3b4-multi-center-randomized-open-label-long-term-safety-study-of-deucravacitinib-in-comparison-to-ustekinumab-in-participants-with-moderate-to-severe-plaque-psoriasis-pragmatyk-r28/ 2026-07-10T02:00:00+02:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/a-phase-3-multicenter-open-label-study-to-evaluate-the-long-term-safety-tolerability-and-efficacy-of-tak-279-in-subjects-with-moderate-to-severe-plaque-psoriasis-r24/ 2026-07-07T02:00:00+02:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/an-extension-study-in-patients-with-moderate-to-severe-plaque-psoriasis-to-evaluate-the-long-term-safety-efficacy-and-durability-of-response-to-esk-001-onward3-r23/ 2026-07-07T02:00:00+02:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/a-phase-3-multicenter-randomized-double-blind-placebo-controlled-and-deucravacitinib-active-comparator-controlled-study-to-evaluate-the-efficacy-and-safety-of-jnj-77242113-for-the-treatment-of-participants-with-moderate-to-severe-plaque-psoriasis-r25/ 2026-07-07T02:00:00+02:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/a-phase-3-multicenter-randomized-double-blind-placebo-controlled-and-deucravacitinib-active-comparator-controlled-study-to-evaluate-the-efficacy-and-safety-of-jnj-77242113-for-the-treatment-of-participants-with-moderate-to-severe-plaque-psoriasis-r21/ 2026-07-03T02:00:00+02:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/a-phase-3-randomized-multicenter-double-blind-placebo-controlled-trial-to-evaluate-the-efficacy-safety-tolerability-and-pharmacokinetics-of-zasocitinib-in-pediatric-participants-aged-4-to-less-than-18-years-with-moderate-to-severe-plaque-psoriasis-r20/ 2026-07-02T02:00:00+02:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/a-phase-3-randomized-multicenter-double-blind-placebo-controlled-trial-to-evaluate-the-efficacy-safety-tolerability-and-pharmacokinetics-of-zasocitinib-in-pediatric-participants-aged-4-to-less-than-18-years-with-moderate-to-severe-plaque-psoriasis-r22/ 2026-07-02T02:00:00+02:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/a-phase-3b-exploratory-multicenter-open-label-study-to-evaluate-the-effect-of-bimekizumab-on-gene-expression-biomarkers-in-study-participants-with-moderate-to-severe-plaque-psoriasis-r19/ 2026-03-08T01:00:00+01:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/a-multicenter-randomized-double-blind-placebo-controlled-phase-3-study-to-evaluate-the-efficacy-safety-and-pharmacokinetics-of-deucravacitinib-in-adolescent-subjects-12-years-to-less-than-18-years-with-moderate-to-severe-plaque-psoriasis-r18/ 2026-03-06T01:00:00+01:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/a-phase-iii-randomized-double-blind-placebo-controlled-study-to-demonstrate-the-efficacy-and-safety-of-tildrakizumab-in-anti-tnf-experienced-subjects-with-active-psoriatic-arthritis-i-inspire-1-r17/ 2026-02-24T01:00:00+01:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/molecular-inflammation-board-at-the-center-for-personalized-medicine-r15/ 2025-08-20T06:00:00+02:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/long-term-safety-study-of-deucravacitinib-versus-ustekinumab-in-participants-with-psoriasis-pragmatyk-r16/ 2025-08-14T06:00:00+02:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/a-phase-3-parallel-group-randomized-double-blind-3-arm-placebo-controlled-multicenter-study-to-investigate-the-efficacy-and-safety-of-subcutaneous-sonelokimab-in-male-and-female-participants-aged-18-years-and-over-with-active-psoriatic-arthritis-who-are-n-r1/ 2025-05-31T02:00:00+02:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/a-phase-3-parallel-group-randomized-double-blind-4-arm-placebo-controlled-multicenter-study-with-risankizumab-as-active-reference-arm-to-investigate-the-efficacy-and-safety-of-subcutaneous-sonelokimab-in-male-and-female-participants-aged-18-years-and-over-r2/ 2025-05-31T02:00:00+02:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/a-multicenter-randomized-double-blind-placebo-and-active-comparator-controlled-phase-3-study-to-evaluate-the-efficacy-and-safety-of-esk-001-in-patients-with-moderate-to-severe-plaque-psoriasis-onward1-r3/ 2025-05-31T02:00:00+02:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/a-study-to-evaluate-the-efficacy-safety-and-drug-levels-of-deucravacitinib-bms-986165-in-adolescent-participants-with-moderate-to-severe-plaque-psoriasis-r6/ 2025-05-29T06:00:00+02:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/an-open-label-multi-center-extension-study-to-characterize-the-long-term-safety-and-efficacy-of-bms-986165-in-subjects-with-moderate-to-severe-plaque-psoriasis-r4/ 2025-05-28T02:00:00+02:00 1 https://www.psoriasis-news.de/neue-studien-in-deutschland/22104-a-randomized-double-blind-placebo-controlled-multicenter-phase-2b3-study-to-evaluate-the-efficacy-and-safety-of-izokibep-in-subjects-with-active-psoriatic-arthritis-r5/ 2025-05-28T02:00:00+02:00 1